Please ensure Javascript is enabled for purposes of website accessibility

Why Intercept Pharmaceuticals Inc is Skyrocketing Today

By Brian Feroldi - Feb 12, 2016 at 3:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Buyout rumors send the clinical stage biopharma's shares higher.

What: Shares of Intercept Pharmaceuticals (ICPT 1.50%), a clinical stage biopharmaceutical company focused on treating diseases of the liver and intestines, jumped more than 27% as of 2:45 p.m. EST Friday after Reuters reported that the company might be looking to sell itself.

So what: According to "sources familiar with the matter" Intercept has been working with a group of investment bankers recently to "explore the prospect of a sale."

It should be emphasized that this is still a rumor at this point as Intercept declined to comment.

Now what: This isn't the first time that rumors have floated around that Intercept might be a buyout target as roughly a year ago another reported surfaced saying that the company could action itself off as it received interest from a handful of large pharma companies that including Gilead Sciences (GILD 0.61%).

If Friday's rumors do prove to be true, then Gilead Sciences might be an ideal acquirer for Intercept as it already has a strong position the liver disease markets, so Intercept could be an interesting strategic fit. It's also worth remembering that Gilead Sciences ended 2015 with $26.2 billion in cash, so it has plenty of capital to make an acquisition if it choose to. For comparison, even with today's pop Intercept's current market value is roughly $3 billion.

Regardless of whether this rumor turns out to be true or not Intercept investors should have an exciting year ahead. The FDA is currently reviewing its compound Obeticholic Acid as a treatment for primary biliary cholangitis and it has set a PDUFA date of May 29, 2016. In addition, the FDA will also be holding an advisory committee meeting of April 7, 2016, so shareholders should have a good idea about the drugs chances of approval in a few short months time.

Brian Feroldi owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.38 (0.61%) $0.38
Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
ICPT
$16.91 (1.50%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.